Last week the FDA made a bold move by requesting that Endo Pharmaceuticals remove its opioid pain medication, reformulated OPANA® ER (oxymorphone hydrochloride), from the market, stating the agency’s concern that “the benefits of the drug may no longer outweigh the risks.” This action – the first time the FDA has taken steps to remove […]
Read more
May 31, 2017 – New FDA Commissioner Scott Gottlieb’s initial tasks largely will be administrative, according to Wayne Pines, healthcare president at APCO Worldwide and former FDA associate commissioner for public affairs, who spoke at a May 16 session of the Coalition for Healthcare Communication Rising Leaders Conference for Healthcare Policy, held in Washington, D.C. […]
Read moreMay 1, 2017 – Having cleared the Senate Committee on Health, Education, Labor and Pensions (HELP) with a 14-9 vote on April 27, Dr. Scott Gottlieb’s nomination to be the next FDA commissioner is now headed for a full Senate vote. So far, Gottlieb’s nomination has moved quickly and smoothly through the nomination process. “Gottlieb […]
Read more March 20, 2017 – Although medical marketers are very familiar with Scott Gottlieb, President Donald Trump’s choice for the top job at the FDA and a former FDA deputy commissioner for medical and scientific affairs, they can only make educated guesses about how he will run the agency of 14,000 people and what his positions […]
Read more